Clinical trials: Daptomycin
Soft Tissue Infections
Phase 2 Safety and Efficacy Study of Daptomycin in Complicated Skin and Skin Structure Infections
multicenter, randomized (1:1), semi-single blind study comparing the safety and efficacy of HDSD daptomycin (10 mg/kg q24h for 4 days) with that of comparator (vancomycin +/- SSP for 7-14 days) in patients with cSSSI due to…
- Trial name
- NCT00426933
- Testing
- Daptomycin, Vancomycin
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Wound Infections
Cubicin(R) for Complicated Post-surgical Wound Infections
The purpose of the study is to describe the clinical efficacy of CUBICIN therapy in patients with superficial and deep post-surgical Gram-positive wound infections
- Trial name
- PSW (NCT00651131)
- Testing
- daptomycin
- Volunteers
- 69 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Staphylococcal Skin Infections
Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-structure Infections
This study will evaluate the safety and efficacy of daptomycin against complicated skin and skin-structure infections in adults
- Trial name
- NCT00463801
- Testing
- Daptomycin
- Where
- 2 sites in Italy
- Volunteers
- 52 people
- Sponsor
- Novartis
Bacteremia
Safety & Efficacy of Daptomycin Versus Standard of Care (SOC) in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
The intent of this study is to describe the safety and efficacy of daptomycin versus standard of care (SOC) in pediatric participants aged 1-17 years with bacteremia caused by Staphylococcus aureus (S. aureus).
- Trial name
- NCT01728376
- Testing
- Daptomycin, Comparator
- Volunteers
- 82 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Bacteremia, Soft Tissue Infections
Safety, Efficacy, and Pharmacokinetics (PK) of Daptomycin (MK-3009) in Japanese Pediatric Subjects With Complicated Skin and Soft Tissue Infections (cSSTI) and Bacteremia (MK-3009-029)
The purpose of this study is to assess the safety, efficacy and pharmacokinetic (PK) parameters of daptomycin for injection in Japanese pediatric participants aged 1 to 17 years with complicated skin and soft tissue infection…
- Conditions
- Bacteremia, Soft Tissue Infections, Skin Diseases, Infectious
- Trial name
- NCT03643952
- Testing
- Daptomycin for Injection
- Where
- 16 sites in Japan
- Volunteers
- 18 people
- Sponsor
- Merck Sharp & Dohme LLC
Acute Hematogenous Osteomyelitis
Safety and Efficacy Study of Daptomycin Compared to Active Comparator in Pediatric Participants With Acute Hematogenous Osteomyelitis (AHO) (MK-3009-006)
The purpose of the study is to determine whether daptomycin is effective and safe in the treatment of pediatric participants with AHO when compared to vancomycin (or equivalent) or nafcillin (or β-lactam equivalent).
- Trial name
- NCT01922011
- Testing
- Daptomycin, Vancomycin (or equivalent), Nafcillin (or equivalent)
- Volunteers
- 149 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Complicated Skin and Skin Structure Infections, S. Aureus Bacteremia
Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment
This is a multicenter, randomized, evaluator-blinded, comparator-controlled study. Participants were to be randomized (1:1) to daptomycin or comparator, stratified by degree of renal impairment (creatinine clearance [CLcr] 30 …
- Conditions
- Complicated Skin and Skin Structure Infections, S. Aureus Bacteremia, Renal Impairment
- Trial name
- RENSE (NCT01104662)
- Testing
- Vancomycin, Daptomycin, Semi-Synthetic Penicillin
- Where
- 10 sites in United States
- Volunteers
- 92 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
S. Aureus Bloodstream Infection
Collect Clinical Data in Chinese Patients Received CUBICIN Treatment for Actual Usage in Clinical Practice
This is a Multicenter, observational, non-interventional registry designed to collect clinical data in Chinese patients who have received CUBICIN treatment under condition of actual usage in clinical practice.
- Trial name
- NCT01212601
- Where
- 18 sites in China
- Volunteers
- 203 people
- Sponsor
- AstraZeneca
Gram-positive Bacterial Infections
Study of Single Dose Daptomycin in Pediatric Patients With Gram-positive Infection for Which They Are Receiving Standard Antibiotics
The purpose of this study is to evaluate the pharmacokinetics of a single dose of daptomycin in patients aged 2-17 years old who have a suspected or proven gram-positive infection for which they are receiving standard antibiotic…
- Trial name
- NCT00136292
- Testing
- daptomycin
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Gram Positive Bacterial Infection
Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven or Suspected Gram-positive Infections or Peri-Operative Subjects Receiving Prophylactic Antibiotics
This is a research study designed to look at the pharmacokinetics (distribution, breakdown, and removal) and tolerability of a single dose of daptomycin in patients aged 3 months to 24 months who have proven or suspected…
- Trial name
- NCT01019395
- Testing
- Daptomycin
- Where
- 8 sites in United States
- Volunteers
- 23 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Staphylococcus Aureus Bacteremia
Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia
The purpose of this study was to compare the efficacy and safety of ceftobiprole medocaril versus a comparator in the treatment of patients with complicated Staphylococcus aureus bacteremia (SAB).
- Trial name
- NCT03138733
- Testing
- Ceftobiprole medocaril, Daptomycin
- Where
- 60 sites in United States, Argentina and 15 more
- Volunteers
- 390 people
- Sponsor
- Basilea Pharmaceutica
Infections
Study to Compare Efficacy and Safety of Daptomycin in Elderly Patients With Complicated Skin and Soft Tissue Infections
The purpose of this study is to provide data documenting the efficacy of daptomycin in elderly patients aged ≥ 65 years with complicated Skin and Soft Tissue Infections.
- Trial name
- NCT01184872
- Testing
- Daptomycin, Vancomycin or Semi-Synthetic Penicillins (SSPs)
- Where
- 17 sites in Austria, Germany and 3 more
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
Staphylococcal Infection
A Study of MK-3009 in Japanese Patients With Skin or Blood Stream Infections Caused by Methicillin-resistant Staphylococcus Aureus (MK-3009-002)
The study investigates the efficacy and safety of MK-3009 in participants with skin infections, septicemia and right-sided infective endocarditis (RIE) caused by methicillin-resistant Staphylococcus aureus (MRSA).
- Trial name
- NCT00770341
- Testing
- Daptomycin 4 mg/kg, Comparator: vancomycin, Daptomycin 6 mg/kg
- Volunteers
- 122 people
- Sponsor
- Merck Sharp & Dohme LLC
Complicated Skin and Skin Structure Infections and Bacteremia Including Right-sided Endocarditis
Safety and Efficacy Study of CUBICIN (Daptomycin) Under Conditions of Actual Use
The purpose of this study is to monitor the safety and efficacy of CUBICIN under conditions of actual use in patients who are diagnosed with complicated Skin and Skin Structure infection (cSSI) or Staphylococcus aureus bacteria…
- Trial name
- NCT01219114
- Where
- 5 sites in Philippines
- Volunteers
- 200 people
- Sponsor
- AstraZeneca
Skin Diseases, Infectious
Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections
This is a multi-center, evaluator-blinded, randomized, comparative study designed to assess the safety, efficacy, and pharmacokinetics (PK) of daptomycin in pediatric subjects ages 1 to 17 years, inclusive, with complicated skin…
- Trial name
- NCT00711802
- Testing
- Daptomycin, Standard of Care (SOC)
- Where
- 30 sites in United States, India and 1 more
- Volunteers
- 396 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Cellulitis
Study Comparing CUBICIN® (Daptomycin for Injection) With Vancomycin in Cellulitis or Erysipelas
This study is designed to investigate the difference in speed and degree of symptom resolution between daptomycin and vancomycin in subjects treated for cellulitis or erysipelas by evaluation of the following parameters: Time to…
- Trial name
- NCT00295178
- Testing
- Daptomycin, Vancomycin
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Staphylococcal Skin Infections
Daptomycin Versus Vancomycin in Participants With Skin Infections Due to MRSA
This was a real-world, prospective, open-label, multicenter study in which participants were randomized (1:1) to receive intravenous (IV) vancomycin or IV daptomycin.
- Trial name
- DAPHEOR1006 (NCT01419184)
- Testing
- Daptomycin, Vancomycin
- Where
- 26 sites in United States, Puerto Rico
- Volunteers
- 250 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
End-stage Renal Disease, Renal Failure Chronic Requiring Hemodialysis
Study to Evaluate Daptomycin Given During Dialysis and After Dialysis
The purpose of this study is to determine whether daptomycin at a higher dose given during the last 30 minutes of a dialysis session is equal to a lower dose of daptomycin given after a dialysis session.
- Trial name
- NCT00882557
- Testing
- daptomycin
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Antibiotic
The Efficacy and Safety of Daptomycin in the Treatment of Gram-positive Bacterial Infection.
This study aims to collect and analyze clinical data of daptomycin to explore the efficacy and safety of daptomycin in the treatment of Gram-positive bacterial infections. And optimize the dosing regimen based on these data.
- Trial name
- NCT04546815
- Testing
- Daptomycin
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Jiangsu Hengrui Pharmaceutical Co., Ltd.
Osteomyelitis
Study of Daptomycin in Subjects Undergoing Surgery for Osteomyelitis Associated With an Infected Prosthetic Caused by Staphylococci
This is a research study designed to look at the efficacy and safety of daptomycin given at a dose of 6 mg/kg or 8 mg/kg in subjects being treated for prosthetic hip or knee infections caused by Staphylococci.
- Trial name
- NCT00428844
- Testing
- daptomycin, vancomycin, teicoplanin
- Where
- 26 sites in United States, Russia and 1 more
- Volunteers
- 75 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)